angiotensin ii has been researched along with fenofibrate in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (60.00) | 29.6817 |
| 2010's | 6 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Barbosa-Sicard, E; Dechend, R; Fiebeler, A; Haller, H; Honeck, H; Kaergel, E; Kirsch, T; Luft, FC; Markovic, M; Muller, DN; Park, JK; Rothe, M; Schunck, WH; Shagdarsuren, E; Theuer, J; Wellner, M | 1 |
| Amiri, F; Benkirane, K; Cohn, JS; Diep, QN; Endemann, D; Schiffrin, EL | 1 |
| Bohman, Q; Flasch, A; Roman, RJ; Stec, DE; Taylor, M; Vera, T | 1 |
| Bak, S; Coleman, T; Osher, E; Semenkovich, CF; Stern, N; Tordjman, KM; Vechoropoulos, M; Yudovich, R | 1 |
| Banks, T; Oyekan, A | 1 |
| Ji, YY; Liu, CH; Liu, JT; Liu, N; Wang, ZD | 1 |
| Ji, YY; Liu, JT; Liu, N; Wang, ZD | 1 |
| Chang, YS; Chung, HW; Chung, S; Kim, HW; Lee, JH; Lim, JH; Park, CW; Shin, SJ; Youn, DY | 1 |
| Campbell, JH; Cullen, B; Daugherty, A; Golledge, J; Moran, CS; Norman, PE; Rush, C; Secomb, E; Wood, F | 1 |
| Pan, H; Sun, X; Tan, H; Yu, Y | 1 |
| Golledge, J; Krishna, SM; Moxon, JV; Norman, PE; Rush, C; Seto, SW; Walker, PJ | 1 |
| Chao, X; Chen, J; Geng, B; Le, K; Liu, P; Liu, Z; Luo, J; Xu, S; Ye, J; Zeng, S; Zou, J | 1 |
| Carreón-Torres, E; Del Valle-Mondragón, L; Díaz-Díaz, E; Guarner-Lans, V; Ibarra-Lara, L; Rubio-Ruiz, ME; Sánchez-Aguilar, M; Sánchez-Mendoza, A; Soria-Castro, E; Vázquez-Meza, H | 1 |
| Alhalabi, O; Antoniak, S; Fang, C; Grobe, N; Mackman, N; Merkulova, A; Schmaier, AH; Stavrou, EX | 1 |
15 other study(ies) available for angiotensin ii and fenofibrate
| Article | Year |
|---|---|
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
A peroxisome proliferator-activated receptor-alpha activator induces renal CYP2C23 activity and protects from angiotensin II-induced renal injury.
Topics: 8,11,14-Eicosatrienoic Acid; Angiotensin II; Angiotensinogen; Animals; Animals, Genetically Modified; Arachidonic Acid; Blotting, Western; Chromatography, Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 Enzyme System; Fenofibrate; Humans; Hypertension; Hypolipidemic Agents; Immunohistochemistry; Kidney; Kidney Diseases; Mass Spectrometry; NF-kappa B; Polymerase Chain Reaction; Rats; Receptors, Cytoplasmic and Nuclear; Renin; Transcription Factors; Vasoconstrictor Agents | 2004 |
PPAR alpha activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats.
Topics: Angiotensin II; Animals; Blood Pressure; Collagen; Electrocardiography; Fenofibrate; Fibrosis; Heart; Hypertension; Inflammation; Infusions, Intravenous; Intercellular Adhesion Molecule-1; Myocardium; NF-kappa B; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Transcription Factors; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2004 |
Fenofibrate prevents the development of angiotensin II-dependent hypertension in mice.
Topics: Angiotensin II; Animals; Blood Pressure; Cytochrome P-450 CYP4A; Cytochrome P-450 Enzyme System; Fenofibrate; Hydroxyeicosatetraenoic Acids; Hypertension; Kidney; Male; Mice; Mice, Inbred C57BL; Vasoconstrictor Agents | 2005 |
Absence of peroxisome proliferator-activated receptor-alpha abolishes hypertension and attenuates atherosclerosis in the Tsukuba hypertensive mouse.
Topics: Aldosterone; Angiotensin II; Animals; Atherosclerosis; Blood Pressure; Cardiomegaly; Diet, Atherogenic; Disease Models, Animal; Fenofibrate; Genotype; Humans; Hypertension; Hypolipidemic Agents; Mice; Mice, Knockout; Mice, Transgenic; PPAR alpha; Renin; Renin-Angiotensin System | 2007 |
Peroxisome proliferator-activated receptor alpha activation attenuated angiotensin type 1-mediated but enhanced angiotensin type 2-mediated hemodynamic effects to angiotensin II in the rat.
Topics: Angiotensin II; Animals; Cardiovascular Agents; Clofibrate; Fenofibrate; Hemodynamics; Male; Models, Animal; Nitric Oxide; PPAR alpha; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2 | 2008 |
PPARalpha activator fenofibrate modulates angiotensin II-induced inflammatory responses in vascular smooth muscle cells via the TLR4-dependent signaling pathway.
Topics: Angiotensin II; Animals; Base Sequence; Blotting, Western; Cells, Cultured; DNA Primers; Enzyme-Linked Immunosorbent Assay; Fenofibrate; Fluorescent Antibody Technique; Inflammation; Male; Muscle, Smooth, Vascular; Polymerase Chain Reaction; PPAR alpha; Rats; Rats, Sprague-Dawley; RNA, Small Interfering; Signal Transduction; Toll-Like Receptor 4 | 2009 |
[Inhibitory effect of fenofibrate on angiotensin II-induced toll-like receptor 4 expression, myeloperoxidase activity and expression in RAW264.7 cells].
Topics: Angiotensin II; Animals; Anti-Inflammatory Agents; Cell Line; Dose-Response Relationship, Drug; Fenofibrate; Hypolipidemic Agents; Lipopolysaccharides; Macrophages; Mice; Peroxidase; RNA, Messenger; Signal Transduction; Toll-Like Receptor 4 | 2009 |
Peroxisome proliferator-activated receptor-alpha activator fenofibrate prevents high-fat diet-induced renal lipotoxicity in spontaneously hypertensive rats.
Topics: Adiponectin; Adipose Tissue; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Dietary Fats; Fenofibrate; Glycated Hemoglobin; Immunohistochemistry; Kidney Diseases; Kidney Function Tests; Lipid Metabolism; Male; Oxidative Stress; PPAR alpha; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Renin-Angiotensin System; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2009 |
Peroxisome proliferator-activated receptor ligands reduce aortic dilatation in a mouse model of aortic aneurysm.
Topics: Angiotensin II; Animals; Aortic Aneurysm, Abdominal; Apolipoproteins E; Fenofibrate; Immunohistochemistry; Ligands; Macrophages; Male; Mice; Osteopontin; Peroxisome Proliferator-Activated Receptors; Pioglitazone; Thiazolidinediones; Up-Regulation | 2010 |
High free fatty acids level related with cardiac dysfunction in obese rats.
Topics: Angiotensin II; Animals; Biomarkers; Diet, High-Fat; Fatty Acids, Nonesterified; Fenofibrate; Heart Failure; Immunohistochemistry; Male; Myocardial Contraction; Myocardium; NF-kappa B; Nitric Oxide Synthase Type II; Obesity; Random Allocation; Rats; Rats, Sprague-Dawley; Renin-Angiotensin System; Triglycerides | 2012 |
Fenofibrate increases high-density lipoprotein and sphingosine 1 phosphate concentrations limiting abdominal aortic aneurysm progression in a mouse model.
Topics: Angiotensin II; Animals; Aorta; Aorta, Thoracic; Aortic Aneurysm, Abdominal; Apoptosis; Azo Compounds; Dilatation, Pathologic; Disease Models, Animal; Disease Progression; Endothelial Cells; Fenofibrate; Inflammation; Kidney; Lipoproteins, HDL; Lysophospholipids; Male; Mice; Mice, Inbred C57BL; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Proto-Oncogene Proteins c-akt; Receptors, Lysosphingolipid; Sphingosine; Treatment Outcome; Up-Regulation | 2012 |
Fenofibrate ameliorates cardiac hypertrophy by activation of peroxisome proliferator-activated receptor-α partly via preventing p65-NFκB binding to NFATc4.
Topics: Angiotensin II; Animals; Cardiomegaly; Cells, Cultured; Enzyme Activation; Fenofibrate; Hypolipidemic Agents; Male; Myocytes, Cardiac; Nerve Tissue Proteins; NFATC Transcription Factors; PPAR alpha; PPAR gamma; Protein Binding; Rats; Rats, Sprague-Dawley; Signal Transduction; Transcription Factor RelA | 2013 |
Fenofibrate Therapy Restores Antioxidant Protection and Improves Myocardial Insulin Resistance in a Rat Model of Metabolic Syndrome and Myocardial Ischemia: The Role of Angiotensin II.
Topics: Angiotensin II; Animals; Antioxidants; Catalase; Disease Models, Animal; Fenofibrate; Insulin; Insulin Resistance; Male; Metabolic Syndrome; Myocardial Infarction; NADPH Oxidase 4; NADPH Oxidases; Nitric Oxide Synthase Type III; Oxidative Stress; Phosphoinositide-3 Kinase Inhibitors; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Superoxide Dismutase; Superoxide Dismutase-1; Triglycerides | 2016 |
Reduced thrombosis in Klkb1-/- mice is mediated by increased Mas receptor, prostacyclin, Sirt1, and KLF4 and decreased tissue factor.
Topics: Angiotensin II; Animals; Carotid Artery Thrombosis; Epoprostenol; Imidazoles; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Mice; Mice, Knockout; Naphthalenes; Nerve Tissue Proteins; Partial Thromboplastin Time; Peptide Fragments; Prekallikrein; Proto-Oncogene Mas; Proto-Oncogene Proteins; Pyrones; Receptor, Bradykinin B2; Receptors, G-Protein-Coupled; RNA, Messenger; Sirtuin 1; Sulfonamides; Synaptotagmins; Thromboplastin | 2015 |